

Douglas L Mann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3600396/publications.pdf>

Version: 2024-02-01

376
papers

38,276
citations

2802

94
h-index

3182

186
g-index

390
all docs

390
docs citations

390
times ranked

32701
citing authors

#	ARTICLE	IF	CITATIONS
1	The Seattle Heart Failure Model. <i>Circulation</i> , 2006, 113, 1424-1433.	1.6	1,744
2	Embryonic and Adult-Derived Resident Cardiac Macrophages Are Maintained through Distinct Mechanisms at Steady State and during Inflammation. <i>Immunity</i> , 2014, 40, 91-104.	14.3	1,120
3	Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD). <i>Journal of the American College of Cardiology</i> , 1996, 27, 1201-1206.	2.8	1,098
4	Targeted Anticytokine Therapy in Patients With Chronic Heart Failure. <i>Circulation</i> , 2004, 109, 1594-1602.	1.6	1,062
5	Effect of Phosphodiesterase-5 Inhibition on Exercise Capacity and Clinical Status in Heart Failure With Preserved Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 309, 1268.	7.4	976
6	Cytokines and Cytokine Receptors in Advanced Heart Failure. <i>Circulation</i> , 2001, 103, 2055-2059.	1.6	903
7	Inflammatory Mediators and the Failing Heart. <i>Circulation Research</i> , 2002, 91, 988-998.	4.5	886
8	Tumor Necrosis Factor- α and Tumor Necrosis Factor Receptors in the Failing Human Heart. <i>Circulation</i> , 1996, 93, 704-711.	1.6	833
9	Pathophysiologically Relevant Concentrations of Tumor Necrosis Factor- α Promote Progressive Left Ventricular Dysfunction and Remodeling in Rats. <i>Circulation</i> , 1998, 97, 1382-1391.	1.6	773
10	Mechanisms and Models in Heart Failure. <i>Circulation</i> , 2005, 111, 2837-2849.	1.6	740
11	Mechanisms and Models in Heart Failure. <i>Circulation</i> , 1999, 100, 999-1008.	1.6	706
12	Distinct macrophage lineages contribute to disparate patterns of cardiac recovery and remodeling in the neonatal and adult heart. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 16029-16034.	7.1	576
13	Innate Immunity and the Failing Heart. <i>Circulation Research</i> , 2015, 116, 1254-1268.	4.5	535
14	Controlled Trial of Intravenous Immune Globulin in Recent-Onset Dilated Cardiomyopathy. <i>Circulation</i> , 2001, 103, 2254-2259.	1.6	515
15	Warfarin and Aspirin in Patients with Heart Failure and Sinus Rhythm. <i>New England Journal of Medicine</i> , 2012, 366, 1859-1869.	27.0	511
16	TNF- α acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle. <i>FASEB Journal</i> , 2005, 19, 362-370.	0.5	510
17	Role of innate and adaptive immune mechanisms in cardiac injury and repair. <i>Nature Reviews Immunology</i> , 2015, 15, 117-129.	22.7	479
18	Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 500.	7.4	457

#	ARTICLE	IF	CITATIONS
19	Desmin Mutation Responsible for Idiopathic Dilated Cardiomyopathy. <i>Circulation</i> , 1999, 100, 461-464.	1.6	420
20	Low-Dose Dopamine or Low-Dose Nesiritide in Acute Heart Failure With Renal Dysfunction. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2533.	7.4	410
21	Endogenous tumor necrosis factor protects the adult cardiac myocyte against ischemic-induced apoptosis in a murine model of acute myocardial infarction. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 5456-5461.	7.1	401
22	Basic mechanisms in heart failure: The cytokine hypothesis. <i>Journal of Cardiac Failure</i> , 1996, 2, 243-249.	1.7	392
23	Deep RNA Sequencing Reveals Dynamic Regulation of Myocardial Noncoding RNAs in Failing Human Heart and Remodeling With Mechanical Circulatory Support. <i>Circulation</i> , 2014, 129, 1009-1021.	1.6	391
24	Reappraising the role of inflammation in heart failure. <i>Nature Reviews Cardiology</i> , 2020, 17, 269-285.	13.7	389
25	Safety and Efficacy of a Soluble P75 Tumor Necrosis Factor Receptor (Enbrel, Etanercept) in Patients With Advanced Heart Failure. <i>Circulation</i> , 1999, 99, 3224-3226.	1.6	367
26	Neurohormonal activation in heart failure with reduced ejection fraction. <i>Nature Reviews Cardiology</i> , 2017, 14, 30-38.	13.7	359
27	Results of Targeted Anti-Tumor Necrosis Factor Therapy With Etanercept (ENBREL) in Patients With Advanced Heart Failure. <i>Circulation</i> , 2001, 103, 1044-1047.	1.6	358
28	Tissue Expression and Immunolocalization of Tumor Necrosis Factor- α in Postinfarction Dysfunctional Myocardium. <i>Circulation</i> , 1999, 99, 1492-1498.	1.6	353
29	Left Ventricular Remodeling in Transgenic Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor. <i>Circulation</i> , 2001, 104, 826-831.	1.6	353
30	Basic Mechanisms in Congestive Heart Failure. <i>Chest</i> , 1994, 105, 897-904.	0.8	350
31	Impact of Oxypurinol in Patients With Symptomatic Heart Failure. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2301-2309.	2.8	350
32	A pivotal role for endogenous TGF-beta-activated kinase-1 in the LKB1/AMP-activated protein kinase energy-sensor pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 17378-17383.	7.1	321
33	The Emerging Role of Innate Immunity in the Heart and Vascular System. <i>Circulation Research</i> , 2011, 108, 1133-1145.	4.5	318
34	Sphingosine Mediates the Immediate Negative Inotropic Effects of Tumor Necrosis Factor- α in the Adult Mammalian Cardiac Myocyte. <i>Journal of Biological Chemistry</i> , 1997, 272, 4836-4842.	3.4	307
35	Tumor Necrosis Factor- α Provokes a Hypertrophic Growth Response in Adult Cardiac Myocytes. <i>Circulation</i> , 1997, 95, 1247-1252.	1.6	302
36	Expression and Functional Significance of Tumor Necrosis Factor Receptors in Human Myocardium. <i>Circulation</i> , 1995, 92, 1487-1493.	1.6	284

#	ARTICLE	IF	CITATIONS
37	Vagus Nerve Stimulation for the Treatment of Heart Failure. Journal of the American College of Cardiology, 2016, 68, 149-158.	2.8	283
38	Ferroptotic cell death and TLR4/Trif signaling initiate neutrophil recruitment after heart transplantation. Journal of Clinical Investigation, 2019, 129, 2293-2304.	8.2	283
39	Infectious Complications in Patients With Left Ventricular Assist Device: Etiology and Outcomes in the Continuous-Flow Era. Annals of Thoracic Surgery, 2010, 90, 1270-1277.	1.3	265
40	Prediction of Mode of Death in Heart Failure. Circulation, 2007, 116, 392-398.	1.6	261
41	Stress-Activated Cytokines and The Heart: From Adaptation to Maladaptation. Annual Review of Physiology, 2003, 65, 81-101.	13.1	258
42	In search of new therapeutic targets and strategies for heart failure: recent advances in basic science. Lancet, The, 2011, 378, 704-712.	13.7	257
43	The Emerging Role of MicroRNAs in Cardiac Remodeling and Heart Failure. Circulation Research, 2008, 103, 1072-1083.	4.5	247
44	Hemodynamic Regulation of Tumor Necrosis Factor- α Gene and Protein Expression in Adult Feline Myocardium. Circulation Research, 1997, 81, 187-195.	4.5	240
45	Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients. Circulation, 2015, 131, 1763-1771.	1.6	239
46	Myocardial Recovery and the Failing Heart. Journal of the American College of Cardiology, 2012, 60, 2465-2472.	2.8	229
47	Cardiac-Specific Overexpression of Tumor Necrosis Factor- α Causes Oxidative Stress and Contractile Dysfunction in Mouse Diaphragm. Circulation, 2000, 102, 1690-1696.	1.6	223
48	Active Ghrelin Levels and Active to Total Ghrelin Ratio in Cancer-Induced Cachexia. Journal of Clinical Endocrinology and Metabolism, 2005, 90, 2920-2926.	3.6	222
49	Distribution of lipids in 8,500 men with coronary artery disease. American Journal of Cardiology, 1995, 75, 1196-1201.	1.6	219
50	Mitral valve surgery in heart failure: Insights from the Acorn Clinical Trial. Journal of Thoracic and Cardiovascular Surgery, 2006, 132, 568-577.e4.	0.8	219
51	TNF provokes cardiomyocyte apoptosis and cardiac remodeling through activation of multiple cell death pathways. Journal of Clinical Investigation, 2007, 117, 2692-2701.	8.2	212
52	Efficacy and Safety of Spironolactone in Acute Heart Failure. JAMA Cardiology, 2017, 2, 950.	6.1	199
53	Circulating Interleukin-6 in Severe Heart Failure. American Journal of Cardiology, 1997, 79, 1128-1131.	1.6	195
54	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	2.2	195

#	ARTICLE	IF	CITATIONS
55	Effect of Inorganic Nitrite vs Placebo on Exercise Capacity Among Patients With Heart Failure With Preserved Ejection Fraction. JAMA - Journal of the American Medical Association, 2018, 320, 1764.	7.4	187
56	<i>Escherichia coli</i> LPS-induced LV dysfunction: role of toll-like receptor-4 in the adult heart. American Journal of Physiology - Heart and Circulatory Physiology, 2002, 282, H2316-H2323.	3.2	174
57	Results of the Randomized Aldosterone Antagonism in Heart Failure With Preserved Ejection Fraction Trial (RAAM-PEF). Journal of Cardiac Failure, 2011, 17, 634-642.	1.7	171
58	Differential Expression of Heat Shock Proteins in Normal and Failing Human Hearts. Journal of Molecular and Cellular Cardiology, 1998, 30, 811-818.	1.9	170
59	Biomarkers of inflammation in heart failure. Heart Failure Reviews, 2010, 15, 331-341.	3.9	169
60	Heart Failure With Recovered Left Ventricular Ejection Fraction. Journal of the American College of Cardiology, 2020, 76, 719-734.	2.8	160
61	A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation. JACC: Heart Failure, 2018, 6, 874-883.	4.1	159
62	Cardiovascular Phenotype in HFrEF Patients With or Without Diabetes. Journal of the American College of Cardiology, 2014, 64, 541-549.	2.8	157
63	Activation of Matrix Metalloproteinases in the Failing Human Heart. Circulation, 1998, 98, 1699-1702.	1.6	155
64	Tumor necrosis factor-alpha and myocardial remodeling in progression of heart failure: a current perspective. Cardiovascular Research, 2002, 53, 822-830.	3.8	152
65	Experimental and Clinical Basis for the Use of Statins in Patients With Ischemic and Nonischemic Cardiomyopathy. Journal of the American College of Cardiology, 2008, 51, 415-426.	2.8	144
66	A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial). European Heart Journal, 2015, 36, 2297-2309.	2.2	137
67	Necrotic Myocardial Cells Release Damage-Associated Molecular Patterns That Provoke Fibroblast Activation In Vitro and Trigger Myocardial Inflammation and Fibrosis In Vivo. Journal of the American Heart Association, 2015, 4, e001993.	3.7	136
68	Tumor Necrosis Factor- α Confers Resistance to Hypoxic Injury in the Adult Mammalian Cardiac Myocyte. Circulation, 1998, 97, 1392-1400.	1.6	134
69	Toll-like receptor 2 modulates left ventricular function following ischemia-reperfusion injury. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H503-H509.	3.2	134
70	CD14-Deficient Mice Are Protected Against Lipopolysaccharide-Induced Cardiac Inflammation and Left Ventricular Dysfunction. Circulation, 2002, 106, 2608-2615.	1.6	131
71	Nuclear Factor- κ B Protects the Adult Cardiac Myocyte Against Ischemia-Induced Apoptosis in a Murine Model of Acute Myocardial Infarction. Circulation, 2003, 108, 3075-3078.	1.6	131
72	Rationale and study design of the INcrease Of Vagal Tone in Heart Failure study: INOVATE-HF. American Heart Journal, 2012, 163, 954-962.e1.	2.7	130

#	ARTICLE	IF	CITATIONS
73	Comparable Performance of the Kansas City Cardiomyopathy Questionnaire in Patients With Heart Failure With Preserved and Reduced Ejection Fraction. <i>Circulation: Heart Failure</i> , 2013, 6, 1139-1146.	3.9	130
74	Angiotensin Receptorâ€“Nepriylsin Inhibition in Acute Myocardial Infarction. <i>New England Journal of Medicine</i> , 2021, 385, 1845-1855.	27.0	130
75	Clinical Evaluation of the CorCap Cardiac Support Device in Patients With Dilated Cardiomyopathy. <i>Annals of Thoracic Surgery</i> , 2007, 84, 1226-1235.	1.3	128
76	Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials. <i>Journal of the American College of Cardiology</i> , 1999, 33, 1935-1942.	2.8	126
77	Expression of proinflammatory cytokines in the failing human heart: comparison of recent-onset and end-stage congestive heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2000, 19, 819-824.	0.6	125
78	Role of MicroRNAs in Cardiac Remodeling and Heart Failure. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 171-182.	2.6	123
79	Angiotensin II Induces Tumor Necrosis Factor Biosynthesis in the Adult Mammalian Heart Through a Protein Kinase Câ€“Dependent Pathway. <i>Circulation</i> , 2002, 105, 2198-2205.	1.6	121
80	Oneâ€“year followâ€“up results from AUGMENTâ€“CHF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with Algisyl in the treatment of heart failure. <i>European Journal of Heart Failure</i> , 2016, 18, 314-325.	7.1	118
81	Extracellular matrix remodeling following myocardial injury. <i>Annals of Medicine</i> , 2003, 35, 316-326.	3.8	117
82	Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2005, 288, H461-H468.	3.2	115
83	Load-Dependent and -Independent Regulation of Proinflammatory Cytokine and Cytokine Receptor Gene Expression in the Adult Mammalian Heart. <i>Circulation</i> , 2002, 105, 2192-2197.	1.6	114
84	Cardiac myocyte apoptosis provokes adverse cardiac remodeling in transgenic mice with targeted TNF overexpression. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2004, 287, H1303-H1311.	3.2	113
85	THE ROLE OF CYTOKINES IN THE FAILING HUMAN HEART. <i>Cardiology Clinics</i> , 1998, 16, 645-656.	2.2	109
86	Hemodynamic Effects of Tezosentan, an Intravenous Dual Endothelin Receptor Antagonist, in Patients With Class III to IV Congestive Heart Failure. <i>Circulation</i> , 2001, 103, 973-980.	1.6	108
87	Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a midâ€“range ejection fraction. <i>European Journal of Heart Failure</i> , 2017, 19, 1597-1605.	7.1	108
88	Downregulation of connexin40 and increased prevalence of atrial arrhythmias in transgenic mice with cardiac-restricted overexpression of tumor necrosis factor. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 292, H1561-H1567.	3.2	106
89	Sustained Benefits of the CorCap Cardiac Support Device on Left Ventricular Remodeling: Three Year Follow-up Results From the Acorn Clinical Trial. <i>Annals of Thoracic Surgery</i> , 2007, 84, 1236-1242.	1.3	105
90	Elevated circulating levels of serum tumor necrosis factor-alpha in patients with hemodynamically significant pressure and volume overload. <i>Journal of the American College of Cardiology</i> , 2000, 36, 208-212.	2.8	98

#	ARTICLE	IF	CITATIONS
91	Diabetic Cardiomyopathy. Heart Failure Clinics, 2012, 8, 619-631.	2.1	98
92	Effects of Tumor Necrosis Factor Gene Polymorphisms on Patients With Congestive Heart Failure. Circulation, 1998, 97, 2499-2501.	1.6	97
93	Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. Journal of Cardiac Failure, 2002, 8, 390-398.	1.7	97
94	Adaptive and Maladaptive Effects of SMAD3 Signaling in the Adult Heart After Hemodynamic Pressure Overloading. Circulation: Heart Failure, 2009, 2, 633-642.	3.9	97
95	Inflammatory Mediators and the Failing Heart: A Translational Approach. Current Molecular Medicine, 2003, 3, 161-182.	1.3	96
96	Tumor necrosis factor- α confers cardioprotection through ectopic expression of keratins K8 and K18. Nature Medicine, 2015, 21, 1076-1084.	30.7	93
97	Targeted Anticytokine Therapy and the Failing Heart. American Journal of Cardiology, 2005, 95, 9-16.	1.6	91
98	Cardiorenal Rescue Study in Acute Decompensated Heart Failure: Rationale and Design of CARRESS-HF, for the Heart Failure Clinical Research Network. Journal of Cardiac Failure, 2012, 18, 176-182.	1.7	91
99	Cyclooxygenase-2 Inhibitor Treatment Improves Left Ventricular Function and Mortality in a Murine Model of Doxorubicin-Induced Heart Failure. Circulation, 2004, 109, 1428-1433.	1.6	90
100	Determining the Feasibility of Spinal Cord Neuromodulation for the Treatment of Chronic Systolic Heart Failure. JACC: Heart Failure, 2016, 4, 129-136.	4.1	90
101	Stress activated cytokines and the heart. Cytokine and Growth Factor Reviews, 1996, 7, 341-354.	7.2	89
102	Hypogonadism in male patients with cancer. Cancer, 2006, 106, 2583-2591.	4.1	88
103	Differential Regulation of Mitogen-Activated Protein Kinases in the Failing Human Heart in Response to Mechanical Unloading. Circulation, 2001, 104, 2273-2276.	1.6	87
104	Mitral valve repair in heart failure: Five-year follow-up from the mitral valve replacement stratum of the Acorn randomized trial. Journal of Thoracic and Cardiovascular Surgery, 2011, 142, 569-574.e1.	0.8	87
105	NHLBI's Program for VAD Therapy for Moderately Advanced Heart Failure: The REVIVE-IT Pilot Trial. Journal of Cardiac Failure, 2010, 16, 855-858.	1.7	86
106	Cellular remodeling in heart failure disrupts KATP channel-dependent stress tolerance. EMBO Journal, 2003, 22, 1732-1742.	7.8	85
107	Beneficial effects of the CorCap cardiac support device: Five-year results from the Acorn Trial. Journal of Thoracic and Cardiovascular Surgery, 2012, 143, 1036-1042.	0.8	85
108	Role of inflammatory cells in fibroblast activation. Journal of Molecular and Cellular Cardiology, 2016, 93, 143-148.	1.9	85

#	ARTICLE	IF	CITATIONS
109	Transforming growth factor- β 2 receptor antagonism attenuates myocardial fibrosis in mice with cardiac-restricted overexpression of tumor necrosis factor. Basic Research in Cardiology, 2008, 103, 60-68.	5.9	84
110	Review of Side-Effect Profile of Combination Ezetimibe and Statin Therapy in Randomized Clinical Trials. American Journal of Cardiology, 2008, 101, 1606-1613.	1.6	81
111	Comparison of Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction Among Those With Versus Without Diabetes Mellitus. American Journal of Cardiology, 2010, 105, 373-377.	1.6	81
112	Intra-Aortic Balloon Counterpulsation in Patients With Chronic Heart Failure and Cardiogenic Shock: Clinical Response and Predictors of Stabilization. Journal of Cardiac Failure, 2015, 21, 868-876.	1.7	81
113	Circulating Levels of Tumor Necrosis Factor Correlate With Indexes of Depressed Heart Rate Variability. Chest, 2003, 123, 716-724.	0.8	80
114	Nitric Oxide Provokes Tumor Necrosis Factor- β Expression in Adult Feline Myocardium Through a cGMP-Dependent Pathway. Circulation, 2000, 102, 1302-1307.	1.6	79
115	Extracellular Matrix Turnover and Inflammatory Markers Independently Predict Functional Status and Outcome in Chronic Heart Failure. Journal of Cardiac Failure, 2008, 14, 467-474.	1.7	79
116	The Development of Myocardial Fibrosis in Transgenic Mice With Targeted Overexpression of Tumor Necrosis Factor Requires Mast Cell-Fibroblast Interactions. Circulation, 2011, 124, 2106-2116.	1.6	79
117	An overview of tumor necrosis factor β and the failing human heart. Current Opinion in Cardiology, 1999, 14, 206.	1.8	77
118	Widespread Down-Regulation of Cardiac Mitochondrial and Sarcomeric Genes in Patients With Sepsis*. Critical Care Medicine, 2017, 45, 407-414.	0.9	76
119	Myocardial Proinflammatory Cytokine Expression and Left Ventricular Remodeling in Patients With Chronic Mitral Regurgitation. Circulation, 2003, 107, 831-837.	1.6	75
120	Activation and Functional Significance of the Renin-Angiotensin System in Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor. Circulation, 2003, 108, 598-604.	1.6	73
121	Cross-regulation between the renin-angiotensin system and inflammatory mediators in cardiac hypertrophy and failure. Cardiovascular Research, 2004, 63, 433-442.	3.8	71
122	Proapoptotic Effects of Caspase-1/Interleukin-Converting Enzyme Dominate in Myocardial Ischemia. Circulation Research, 2005, 96, 1103-1109.	4.5	71
123	Recent insights into the role of tumor necrosis factor in the failing heart. , 2001, 6, 71-80.		70
124	Increased Myocardial Gene Expression of Tumor Necrosis Factor- β and Nitric Oxide Synthase-2. Circulation, 2002, 105, 1537-1540.	1.6	68
125	Targeted Overexpression of Noncleavable and Secreted Forms of Tumor Necrosis Factor Provokes Disparate Cardiac Phenotypes. Circulation, 2004, 109, 262-268.	1.6	68
126	Epidemiology and Natural History of Recovery of Left Ventricular Function in Recent Onset Dilated Cardiomyopathies. Current Heart Failure Reports, 2013, 10, 321-330.	3.3	68

#	ARTICLE	IF	CITATIONS
127	Characterization of the Obese Phenotype of Heart Failure With Preserved Ejection Fraction: A RELAX Trial Ancillary Study. Mayo Clinic Proceedings, 2019, 94, 1199-1209.	3.0	68
128	The NHLBI REVIVE-IT study: Understanding its discontinuation in the context of current left ventricular assist device therapy. Journal of Heart and Lung Transplantation, 2016, 35, 1277-1283.	0.6	67
129	Effects of Phosphodiesterase Type 5 Inhibition on Systemic and Pulmonary Hemodynamics and Ventricular Function in Patients With Severe Symptomatic Aortic Stenosis. Circulation, 2012, 125, 2353-2362.	1.6	66
130	Positioning of Inflammatory Biomarkers in the Heart Failure Landscape. Journal of Cardiovascular Translational Research, 2013, 6, 485-492.	2.4	66
131	Abnormal Global Longitudinal Strain Predicts Future Deterioration of Left Ventricular Function in Heart Failure Patients With a Recovered Left Ventricular Ejection Fraction. Circulation: Heart Failure, 2017, 10, .	3.9	65
132	Imaging Systemic Inflammatory Networks in Ischemic Heart Disease. Journal of the American College of Cardiology, 2015, 65, 1583-1591.	2.8	64
133	Modulation of subsets of cardiac B lymphocytes improves cardiac function after acute injury. JCI Insight, 2018, 3, .	5.0	63
134	Desmin mediates TNF- α -induced aggregate formation and intercalated disk reorganization in heart failure. Journal of Cell Biology, 2008, 181, 761-775.	5.2	62
135	SR compartment calcium and cell apoptosis in SERCA overexpression. Cell Calcium, 1999, 26, 25-36.	2.4	61
136	Proteomic Signatures of Heart Failure Relation to Left Ventricular Ejection Fraction. Journal of the American College of Cardiology, 2020, 76, 1982-1994.	2.8	61
137	Cytokines as Emerging Targets in the Treatment of Heart Failure. Trends in Cardiovascular Medicine, 2000, 10, 216-223.	4.9	60
138	The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. Journal of the American College of Cardiology, 2000, 36, 523-528.	2.8	60
139	New Therapeutics for Chronic Heart Failure. Annual Review of Medicine, 2002, 53, 59-74.	12.2	60
140	MicroRNAs and the Failing Heart. New England Journal of Medicine, 2007, 356, 2644-2645.	27.0	60
141	Negative inotropic effects of high-mobility group box 1 protein in isolated contracting cardiac myocytes. American Journal of Physiology - Heart and Circulatory Physiology, 2008, 294, H1490-H1496.	3.2	60
142	The feasibility and safety of Algisyl-LVR ® as a method of left ventricular augmentation in patients with dilated cardiomyopathy: Initial first in man clinical results. International Journal of Cardiology, 2015, 199, 18-24.	1.7	60
143	Brief murine myocardial I/R induces chemokines in a TNF- α -independent manner: role of oxygen radicals. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H2549-H2558.	3.2	59
144	Cross-sectional echocardiographic assessment of regional left ventricular performance and myocardial perfusion. Progress in Cardiovascular Diseases, 1986, 29, 1-52.	3.1	58

#	ARTICLE	IF	CITATIONS
145	Targeted Overexpression of Transmembrane Tumor Necrosis Factor Provokes a Concentric Cardiac Hypertrophic Phenotype. <i>Circulation</i> , 2003, 108, 1002-1008.	1.6	58
146	The Cytoprotective Effects of Tumor Necrosis Factor Are Conveyed Through Tumor Necrosis Factor Receptor-Associated Factor 2 in the Heart. <i>Circulation: Heart Failure</i> , 2010, 3, 157-164.	3.9	58
147	The Adverse Impact of Diabetes Mellitus on Left Ventricular Remodeling and Function in Patients With Severe Aortic Stenosis. <i>Circulation: Heart Failure</i> , 2011, 4, 286-292.	3.9	58
148	Speckle Strain Echocardiography Predicts Outcome in Patients with Heart Failure with both Depressed and Preserved Left Ventricular Ejection Fraction. <i>Echocardiography</i> , 2015, 32, 71-78.	0.9	58
149	Left Ventricular Assist Devices and the Failing Heart. <i>Circulation</i> , 1998, 98, 2367-2369.	1.6	57
150	Myocardial B cells are a subset of circulating lymphocytes with delayed transit through the heart. <i>JCI Insight</i> , 2020, 5, .	5.0	57
151	Rationale, design, and methods for a pivotal randomized clinical trial for the assessment of a cardiac support device in patients with New York health association class III-IV heart failure. <i>Journal of Cardiac Failure</i> , 2004, 10, 185-192.	1.7	55
152	Autonomic Modulation for the Management of Patients with Chronic Heart Failure. <i>Circulation: Heart Failure</i> , 2015, 8, 619-628.	3.9	54
153	Tumor necrosis factor- α and the failing human heart-TNF α and heart failure. <i>Clinical Cardiology</i> , 1995, 18, IV20-IV27.	1.8	53
154	Cytokines in Heart Failure: Pathogenetic Mechanisms and Potential Treatment. <i>Proceedings of the Association of American Physicians</i> , 1999, 111, 423-428.	2.0	53
155	Improving Outcomes in Heart Failure. <i>Circulation</i> , 2002, 105, 2810-2812.	1.6	53
156	Effects of changes in left ventricular contractility on indexes of contractility in mice. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002, 283, H2504-H2510.	3.2	53
157	Structural and Functional Phenotyping of the Failing Heart. <i>JACC: Heart Failure</i> , 2017, 5, 772-781.	4.1	53
158	Functional Significance of Hemodynamic Overload-Induced Expression of Leukemia-Inhibitory Factor in the Adult Mammalian Heart. <i>Circulation</i> , 2001, 103, 1296-1302.	1.6	52
159	Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III-IV congestive heart failure. <i>Expert Opinion on Investigational Drugs</i> , 2004, 13, 1509-1516.	4.1	51
160	Oxidative Stress Promotes Ligand-independent and Enhanced Ligand-dependent Tumor Necrosis Factor Receptor Signaling. <i>Journal of Biological Chemistry</i> , 2008, 283, 23419-23428.	3.4	50
161	Tumor Necrosis Factor Receptor-Associated Factor 2 Mediates Mitochondrial Autophagy. <i>Circulation: Heart Failure</i> , 2015, 8, 175-187.	3.9	49
162	Duality of innate stress responses in cardiac injury, repair, and remodeling. <i>Journal of Molecular and Cellular Cardiology</i> , 2004, 37, 801-811.	1.9	48

#	ARTICLE	IF	CITATIONS
163	Tumor necrosis factor-induced signal transduction and left ventricular remodeling. Journal of Cardiac Failure, 2002, 8, S379-S386.	1.7	46
164	Angiotensin-Receptor Blockade in Acute Myocardial Infarction – A Matter of Dose. New England Journal of Medicine, 2003, 349, 1963-1965.	27.0	46
165	Basic mechanisms of left ventricular remodeling: the contribution of wall stress. Journal of Cardiac Failure, 2004, 10, S202-S206.	1.7	46
166	Neuromodulation of the Failing Heart. JACC Basic To Translational Science, 2016, 1, 95-106.	4.1	46
167	Role of the Innate Immune System in Acute Viral Myocarditis. Basic Research in Cardiology, 2009, 104, 228-237.	5.9	45
168	Cardiac remodelling and myocardial recovery: lost in translation?. European Journal of Heart Failure, 2010, 12, 789-796.	7.1	45
169	Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure. Stroke, 2016, 47, 2031-2037.	2.0	44
170	Impact of Preeclampsia on Clinical and Functional Outcomes in Women With Peripartum Cardiomyopathy. Circulation: Heart Failure, 2017, 10, .	3.9	44
171	Innate immunity in the adult mammalian heart: for whom the cell tolls. Transactions of the American Clinical and Climatological Association, 2010, 121, 34-50; discussion 50-1.	0.5	44
172	Reduced Apolipoprotein M and Adverse Outcomes Across the Spectrum of Human Heart Failure. Circulation, 2020, 141, 1463-1476.	1.6	42
173	Tumor Necrosis Factor and Viral Myocarditis: The Fine Line Between Innate and Inappropriate Immune Responses in the Heart. Circulation, 2001, 103, 626-629.	1.6	41
174	Comparison of symptomatic and functional responses to vagus nerve stimulation in ANTHEM-HF, INOVATE-HF, and NECTAR-HF. ESC Heart Failure, 2020, 7, 76-84.	3.1	41
175	Effects of age on ventricular performance during graded supine exercise. American Heart Journal, 1986, 111, 108-115.	2.7	40
176	Apoptosis and the heart: a decade of progress. Journal of Molecular and Cellular Cardiology, 2005, 38, 1-2.	1.9	40
177	Innate immunity mediates myocardial preconditioning through Toll-like receptor 2 and TIRAP-dependent signaling pathways. American Journal of Physiology - Heart and Circulatory Physiology, 2010, 298, H1079-H1087.	3.2	40
178	The Role of Innate Immune Responses in the Heart in Health and Disease. Trends in Cardiovascular Medicine, 2004, 14, 1-7.	4.9	39
179	Soluble Tumor Necrosis Factor Receptors and Heart Failure Risk in Older Adults. Circulation: Heart Failure, 2014, 7, 5-11.	3.9	39
180	Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 2020, 8, 789-799.	4.1	39

#	ARTICLE	IF	CITATIONS
181	Benefit of Warfarin Compared With Aspirin in Patients With Heart Failure in Sinus Rhythm. Circulation: Heart Failure, 2013, 6, 988-997.	3.9	38
182	Therapeutic targeting of innate immunity in the failing heart. Journal of Molecular and Cellular Cardiology, 2011, 51, 594-599.	1.9	37
183	Load-Dependent Changes in Left Ventricular Structure and Function in a Pathophysiologically Relevant Murine Model of Reversible Heart Failure. Circulation: Heart Failure, 2018, 11, e004351.	3.9	37
184	Cardiac Disease in Cancer Patients: An Overview. Progress in Cardiovascular Diseases, 2010, 53, 80-87.	3.1	36
185	Use of Biomarkers in the Management of Heart Failure. Circulation, 2003, 107, 1231-1233.	1.6	35
186	Inhibition of PPAR- α activity in mice with cardiac-restricted expression of tumor necrosis factor: potential role of TGF- β 2/Smad3. American Journal of Physiology - Heart and Circulatory Physiology, 2007, 292, H1443-H1451.	3.2	35
187	Heart Failure Diagnosis, Readmission, and Mortality Prediction Using Machine Learning and Artificial Intelligence Models. Current Epidemiology Reports, 2020, 7, 212-219.	2.4	35
188	Comparison of outcomes of white versus black patients hospitalized with heart failure and preserved ejection fraction**The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs.. American Journal of Cardiology, 2004, 94, 1003-1007.	1.6	34
189	Left Ventricular Size and Shape: Determinants of Mechanical Signal Transduction Pathways. Heart Failure Reviews, 2005, 10, 95-100.	3.9	34
190	Inflammation and treatment response to sertraline in patients with coronary heart disease and comorbid major depression. Journal of Psychosomatic Research, 2011, 71, 13-17.	2.6	34
191	Functional significance of the discordance between transcriptional profile and left ventricular structure/function during reverse remodeling. JCI Insight, 2016, 1, e86038.	5.0	33
192	Targeted cancer therapeutics: the heartbreak of success. Nature Medicine, 2006, 12, 881-882.	30.7	32
193	The Emerging Role of B Lymphocytes in Cardiovascular Disease. Annual Review of Immunology, 2020, 38, 99-121.	21.8	32
194	Inflammatory mediators in heart failure: homogeneity through heterogeneity. Lancet, The, 1999, 353, 1812-1813.	13.7	31
195	New Predictive Models of Heart Failure Mortality Using Time-Series Measurements and Ensemble Models. Circulation: Heart Failure, 2011, 4, 456-462.	3.9	31
196	Prevalence of lactic acidemia in patients with advanced heart failure and depressed cardiac output. European Journal of Heart Failure, 2017, 19, 1027-1033.	7.1	31
197	Preclinical and clinical assessment of the safety and potential efficacy of thalidomide in heart failure. Journal of Cardiac Failure, 2002, 8, 306-314.	1.7	30
198	Dysferlin Mediates the Cytoprotective Effects of TRAF2 Following Myocardial Ischemia Reperfusion Injury. Journal of the American Heart Association, 2014, 3, e000662.	3.7	30

#	ARTICLE	IF	CITATIONS
199	Left ventricular assist device-induced reverse remodeling: it's not just about myocardial recovery. Expert Review of Medical Devices, 2017, 14, 15-26.	2.8	30
200	Hepcidin in anemia of chronic heart failure. American Journal of Hematology, 2011, 86, 107-109.	4.1	29
201	Tumor Necrosis Factor Receptor-Associated Factor 2 Signaling Provokes Adverse Cardiac Remodeling in the Adult Mammalian Heart. Circulation: Heart Failure, 2013, 6, 535-543.	3.9	29
202	Prognostic Significance of Biomarkers in Predicting Outcome in Patients With Coronary Artery Disease and Left Ventricular Dysfunction. Circulation: Heart Failure, 2013, 6, 461-472.	3.9	28
203	Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial. Circulation, 2022, 145, 87-89.	1.6	28
204	Tumor Necrosis Factor- α Is Persistently Expressed in Cardiac Allografts in the Absence of Histological or Clinical Evidence of Rejection. Transplantation Proceedings, 1998, 30, 875-877.	0.6	27
205	Functional significance of inflammatory mediators in a murine model of resuscitated hemorrhagic shock. American Journal of Physiology - Heart and Circulatory Physiology, 2005, 288, H1272-H1277.	3.2	27
206	Normalization of cardiac structure and function after regression of cardiac hypertrophy. American Heart Journal, 1994, 128, 333-343.	2.7	26
207	Failure of benefit and early hazard of bucindolol for Class IV heart failure. Journal of Cardiac Failure, 2003, 9, 266-277.	1.7	26
208	Advanced Heart Failure and Transplant Cardiology: A Subspecialty Is Born. Journal of the American College of Cardiology, 2009, 53, 834-836.	2.8	26
209	Clinical applications of miRNAs in cardiac remodeling and heart failure. Personalized Medicine, 2010, 7, 531-548.	1.5	26
210	The Heartmate Risk Score Predicts Morbidity and Mortality in Unselected Left Ventricular Assist Device Recipients and Risk Stratifies INTERMACS Class 1 Patients. JACC: Heart Failure, 2015, 3, 283-290.	4.1	26
211	Cognitive Decline Over Time in Patients With Systolic Heart Failure. JACC: Heart Failure, 2019, 7, 1042-1053.	4.1	26
212	Predictive Value of Cardiopulmonary Exercise Testing Parameters in Ambulatory Advanced Heart Failure. JACC: Heart Failure, 2021, 9, 226-236.	4.1	26
213	Heart Failure Guidelines, Performance Measures, and the Practice of Medicine. Journal of the American College of Cardiology, 2010, 56, 2077-2080.	2.8	25
214	Communication in the Heart: the Role of the Innate Immune System in Coordinating Cellular Responses to Ischemic Injury. Journal of Cardiovascular Translational Research, 2012, 5, 827-836.	2.4	25
215	<scp>CHA₂</sub>DS₂</sub>-VASc</scp> score and adverse outcomes in patients with heart failure with reduced ejection fraction and sinus rhythm. European Journal of Heart Failure, 2016, 18, 1261-1266.	7.1	25
216	Left atrial volume and cardiovascular outcomes in systolic heart failure: effect of antithrombotic treatment. ESC Heart Failure, 2018, 5, 800-808.	3.1	25

#	ARTICLE	IF	CITATIONS
217	New Insights into Mechanisms of Action of Carvedilol Treatment in Chronic Heart Failure Patientsâ€”A Matter of Time for Contractility. <i>Journal of Cardiac Failure</i> , 2012, 18, 183-193.	1.7	24
218	Is Myocardial Recovery Possible and How Do You Measure It?. <i>Current Cardiology Reports</i> , 2012, 14, 293-298.	2.9	24
219	Serum Biomarkers in Severe Refractory Cardiogenic Shock. <i>JACC: Heart Failure</i> , 2013, 1, 200-206.	4.1	24
220	Recurrent Stroke in the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. <i>Cerebrovascular Diseases</i> , 2014, 38, 176-181.	1.7	24
221	Mechanisms and Models in Heart Failure. <i>Circulation Research</i> , 2021, 128, 1435-1450.	4.5	24
222	Repetitive Myocardial Ischemia Promotes Coronary Growth in the Adult Mammalian Heart. <i>Journal of the American Heart Association</i> , 2013, 2, e000343.	3.7	23
223	Angiotensin II as an inflammatory mediator: evolving concepts in the role of the renin angiotensin system in the failing heart. <i>Cardiovascular Drugs and Therapy</i> , 2002, 16, 7-9.	2.6	22
224	Effect of the Soluble TNFâ€”Antagonist Etanercept on Tumor Necrosis Factor Bioactivity and Stability. <i>Clinical and Translational Science</i> , 2008, 1, 142-145.	3.1	22
225	Circulating p53-Responsive MicroRNAs as Predictive Biomarkers in Heart Failure After Acute Myocardial Infarction. <i>Circulation Research</i> , 2013, 113, 242-244.	4.5	22
226	Recent Insights into the Role of Tumor Necrosis Factor in the Failing Heart. <i>Developments in Cardiovascular Medicine</i> , 2001, , 3-12.	0.1	22
227	Single- versus dual-chamber sensor-driven pacing: Comparison of cardiac outputs. <i>American Heart Journal</i> , 1991, 122, 728-732.	2.7	21
228	Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2013, 6, 862-868.	3.9	21
229	Quality of Anticoagulation Control in Preventing Adverse Events in Patients With Heart Failure in Sinus Rhythm. <i>Circulation: Heart Failure</i> , 2015, 8, 504-509.	3.9	21
230	The HeartMate Risk Score Identifies Patients With Similar Mortality Risk AcrossÂ”All INTERMACS Profiles in aÂ”LargeÂ”Multicenter Analysis. <i>JACC: Heart Failure</i> , 2016, 4, 950-958.	4.1	21
231	Plasma concentrations of tumor necrosis factor- in cats with congestive heart failure. <i>American Journal of Veterinary Research</i> , 2002, 63, 640-642.	0.6	20
232	Pathophysiology of Heart Failure. , 2012, , 487-504.		20
233	Digoxin treatment in heart failure â€” Unveiling risk by cluster analysis of DIG data. <i>International Journal of Cardiology</i> , 2011, 150, 264-269.	1.7	19
234	Lifestyle Modification with Diet and Exercise in Obese Patients with Heart Failure â€” A Pilot Study. <i>Journal of Obesity & Weight Loss Therapy</i> , 2012, 02, 1-8.	0.1	19

#	ARTICLE	IF	CITATIONS
235	Cardiac Risk Markers and Response to Depression Treatment in Patients With Coronary Heart Disease. Psychosomatic Medicine, 2016, 78, 49-59.	2.0	19
236	Diagnosis and management of adult hereditary cardio-neuromuscular disorders: A model for the multidisciplinary care of complex genetic disorders. Trends in Cardiovascular Medicine, 2017, 27, 51-58.	4.9	19
237	Immunomodulatory role of nonneuronal cholinergic signaling in myocardial injury. JCI Insight, 2019, 4, .	5.0	19
238	The fractional shortening-velocity ratio: Validation of a new echocardiographic doppler method for identifying patients with significant aortic stenosis. Journal of the American College of Cardiology, 1990, 15, 1578-1584.	2.8	18
239	Contemporary Medical Options for Treating Patients With Heart Failure. Circulation, 2002, 105, 2244-2246.	1.6	18
240	Advanced Heart Failure and Transplant Cardiology: A Subspecialty is Born. Journal of Cardiac Failure, 2009, 15, 98-100.	1.7	18
241	Are Synthetic Data Derivatives the Future of Translational Medicine?. JACC Basic To Translational Science, 2018, 3, 716-718.	4.1	18
242	TNF receptor-activated factor 2 mediates cardiac protection through noncanonical NF- κ B signaling. JCI Insight, 2018, 3, .	5.0	18
243	Effects of Vesnarinone on Peripheral Circulating Levels of Cytokines and Cytokine Receptors in Patients With Heart Failure. Chest, 2001, 120, 453-459.	0.8	17
244	Mitochondrial tolerance to stress impaired in failing heart. Journal of Molecular and Cellular Cardiology, 2003, 35, 1161-1166.	1.9	17
245	The pharmacokinetics of etanercept in patients with heart failure. British Journal of Clinical Pharmacology, 2001, 51, 191-192.	2.4	16
246	Spectrum of Pleiotropic Effects of Statins in Heart Failure. Heart Failure Clinics, 2008, 4, 153-161.	2.1	16
247	COVID-19 Clinical Trials. JACC Basic To Translational Science, 2020, 5, 501-517.	4.1	16
248	Developmental changes in myocardial B cells mirror changes in B cells associated with different organs. JCI Insight, 2020, 5, .	5.0	16
249	Relationship of functional recovery to scar contraction after myocardial infarction in the canine left ventricle. American Heart Journal, 1989, 117, 819-829.	2.7	15
250	Coronary Collaterals Predict Improved Survival and Allograft Function in Patients With Coronary Allograft Vasculopathy. Circulation: Heart Failure, 2013, 6, 773-784.	3.9	15
251	Cognitive Function in Ambulatory Patients with Systolic Heart Failure: Insights from the Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial. PLoS ONE, 2014, 9, e113447.	2.5	15
252	Quality of life and treatment preference for ventricular assist device therapy in ambulatory advanced heart failure: A report from the REVIVAL study. Journal of Heart and Lung Transplantation, 2020, 39, 27-36.	0.6	15

#	ARTICLE	IF	CITATIONS
253	Global, Regional, and National Burden of Myocarditis From 1990 to 2017: A Systematic Analysis Based on the Global Burden of Disease Study 2017. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 692990.	2.4	15
254	Interleukin-6 and Viral Myocarditis: The Yin-Yang of Cardiac Innate Immune Responses. <i>Journal of Molecular and Cellular Cardiology</i> , 2001, 33, 1551-1553.	1.9	14
255	The Emerging Role of Small Non-coding RNAs in the Failing Heart: Big Hopes for Small Molecules. <i>Cardiovascular Drugs and Therapy</i> , 2011, 25, 149-149.	2.6	14
256	Impaired Protein Quality Control During Left Ventricular Remodeling in Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	14
257	Ambulatory Advanced Heart Failure in Women. <i>JACC: Heart Failure</i> , 2019, 7, 602-611.	4.1	14
258	Relation of tissue Doppler-derived myocardial velocities to serum levels and myocardial gene expression of tumor necrosis factor- α and inducible nitric oxide synthase in patients with ischemic cardiomyopathy having coronary artery bypass grafting. <i>American Journal of Cardiology</i> , 2002, 90, 708-712.	1.6	13
259	Designs for Mechanical Circulatory Support Device Studies. <i>Journal of Cardiac Failure</i> , 2007, 13, 63-74.	1.7	13
260	Myocardial Expression Levels of Micro-Ribonucleic Acids in Patients With Left Ventricular Assist Devices. <i>Journal of the American College of Cardiology</i> , 2011, 58, 2279-2281.	2.8	13
261	The first prognostic model for stroke and death in patients with systolic heart failure. <i>Journal of Cardiology</i> , 2016, 68, 100-103.	1.9	13
262	Registry Evaluation of Vital Information for VADs in Ambulatory Life (REVIVAL): Rationale, design, baseline characteristics, and inclusion criteria performance. <i>Journal of Heart and Lung Transplantation</i> , 2020, 39, 7-15.	0.6	13
263	Tumor necrosis factor- γ and tumor necrosis factor receptors in human heart failure. <i>Heart Failure Reviews</i> , 1996, 1, 211-219.	3.9	12
264	The Metabolic Syndrome and Mortality in an Ethnically Diverse Heart Failure Population. <i>Journal of Cardiac Failure</i> , 2008, 14, 590-595.	1.7	12
265	National Institutes of Health Career Development Awards for Cardiovascular Physician-Scientists. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1816-1827.	2.8	12
266	Targeting Myocardial Energetics in the Failing Heart. <i>Circulation: Heart Failure</i> , 2017, 10, .	3.9	12
267	COVID-19 Clinical Trials. <i>JACC: CardioOncology</i> , 2020, 2, 254-269.	4.0	12
268	Management of Heart Failure Patients with Reduced Ejection Fraction. , 2012, , 543-577.		12
269	TNF α decreases β -MHC expression by a NO mediated pathway: role of E-box transcription factors for cardiomyocyte specific gene regulation. <i>Cardiovascular Research</i> , 2002, 53, 460-469.	3.8	11
270	Antiinflammatory therapy in myocarditis. <i>Current Opinion in Cardiology</i> , 2003, 18, 189-193.	1.8	11

#	ARTICLE	IF	CITATIONS
271	Anti-angiotensin Therapy: New Perspectives. <i>Cardiology Clinics</i> , 2007, 25, 573-580.	2.2	11
272	The vagus nerve and autonomic imbalance in heart failure: past, present, and future. <i>Heart Failure Reviews</i> , 2011, 16, 97-99.	3.9	11
273	Clinical and Echocardiographic Factors Associated With New-Onset Atrial Fibrillation in Heart Failure—Subanalysis of the WARCEF Trial. <i>Circulation Journal</i> , 2016, 80, 619-626.	1.6	11
274	The genomics of heart failure: design and rationale of the HERMES consortium. <i>ESC Heart Failure</i> , 2021, 8, 5531-5541.	3.1	11
275	Rethinking Phase II clinical trial design in heart failure. <i>Clinical Investigation</i> , 2013, 3, 57-68.	0.0	11
276	TRAF2, an Innate Immune Sensor, Reciprocally Regulates Mitophagy and Inflammation to Maintain Cardiac Myocyte Homeostasis. <i>JACC Basic To Translational Science</i> , 2022, 7, 223-243.	4.1	11
277	Functional relation between infarct thickness and regional systolic function in the acutely and subacutely infarcted canine left ventricle. <i>Journal of the American College of Cardiology</i> , 1989, 14, 481-488.	2.8	10
278	Treatment of Heart Failure Beyond Practice Guidelines Role of Cardiac Remodeling. <i>Circulation Journal</i> , 2008, 72, A1-A7.	1.6	10
279	Sphingosine 1-Phosphate as a Therapeutic Target in Heart Failure. <i>Circulation</i> , 2012, 125, 2692-2694.	1.6	10
280	Stroke in Heart Failure in Sinus Rhythm: The Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction Trial. <i>Cerebrovascular Diseases</i> , 2013, 36, 74-78.	1.7	9
281	Vagal nerve stimulation for heart failure: new pieces to the puzzle?. <i>European Journal of Heart Failure</i> , 2015, 17, 125-127.	7.1	9
282	Impact of Socioeconomic Factors on Patient Desire for Early LVAD Therapy Prior to Inotrope Dependence. <i>Journal of Cardiac Failure</i> , 2020, 26, 316-323.	1.7	9
283	Advances in Our Clinical Understanding of Autonomic Regulation Therapy Using Vagal Nerve Stimulation in Patients Living With Heart Failure. <i>Frontiers in Physiology</i> , 2022, 13, 857538.	2.8	9
284	Introducing JACC: Basic to Translational Science. <i>JACC Basic To Translational Science</i> , 2016, 1, 1-2.	4.1	8
285	Cardiac Sympathetic-Parasympathetic Interaction. <i>JACC Basic To Translational Science</i> , 2020, 5, 811-814.	4.1	8
286	Unsupervised cluster analysis of patients with recovered left ventricular ejection fraction identifies unique clinical phenotypes. <i>PLoS ONE</i> , 2021, 16, e0248317.	2.5	8
287	Signaling pathways involved in left ventricular remodeling: Summation. <i>Journal of Cardiac Failure</i> , 2002, 8, S387-S388.	1.7	7
288	Statement regarding the pre and post market assessment of durable, implantable ventricular assist devices in the United States. <i>Journal of Heart and Lung Transplantation</i> , 2012, 31, 1241-1252.	0.6	7

#	ARTICLE	IF	CITATIONS
289	Statement Regarding the Pre and Post Market Assessment of Durable, Implantable Ventricular Assist Devices in the United States. <i>Circulation: Heart Failure</i> , 2013, 6, e1-e11.	3.9	7
290	The evolution of modern theory and therapy for heart failure. <i>Progress in Pediatric Cardiology</i> , 2014, 37, 9-12.	0.4	7
291	Bleeding Risk and Antithrombotic Strategy in Patients With Sinus Rhythm and Heart Failure With Reduced Ejection Fraction Treated With Warfarin or Aspirin. <i>American Journal of Cardiology</i> , 2015, 116, 904-912.	1.6	7
292	Is It Time for a New Taxonomy for Heart Failure?. <i>Journal of Cardiac Failure</i> , 2016, 22, 710-712.	1.7	7
293	Beta-blockers for the treatment of heart failure with a mid-range ejection fraction: deja-vu all over again?. <i>European Heart Journal</i> , 2018, 39, 36-38.	2.2	7
294	Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial. <i>ESC Heart Failure</i> , 2019, 6, 297-307.	3.1	7
295	RNA Vaccines for COVID-19. <i>JACC Basic To Translational Science</i> , 2020, 5, 1240-1243.	4.1	7
296	Comorbid Conditions and Health-Related Quality of Life in Ambulatory Heart Failure Patients. <i>Circulation: Heart Failure</i> , 2020, 13, e006858.	3.9	7
297	Caregiver Health-Related Quality of Life, Burden, and Patient Outcomes in Ambulatory Advanced Heart Failure: A Report From REVIVAL. <i>Journal of the American Heart Association</i> , 2021, 10, e019901.	3.7	6
298	Early natural history of regional left ventricular dysfunction after experimental myocardial infarction. <i>American Heart Journal</i> , 1988, 115, 538-546.	2.7	5
299	Heart Failure Guidelines, Performance Measures, and the Practice of Medicine. <i>Journal of Cardiac Failure</i> , 2010, 16, 915-918.	1.7	5
300	Translational medicine: mitigating risks for investigators. <i>Nature Reviews Drug Discovery</i> , 2013, 12, 327-328.	46.4	5
301	How to Build an Integrated Biobank: The Washington University Translational Cardiovascular Biobank & Repository Experience. <i>Clinical and Translational Science</i> , 2013, 6, 226-231.	3.1	5
302	Getting Pumped about Heart Failure. <i>Cell Metabolism</i> , 2014, 19, 896-897.	16.2	5
303	Resting Heart Rate and Ischemic Stroke in Patients with Heart Failure. <i>Cerebrovascular Diseases</i> , 2017, 44, 43-50.	1.7	5
304	The Tafamidis Drug Development Program. <i>JACC Basic To Translational Science</i> , 2018, 3, 871-873.	4.1	5
305	Ischemia reperfusion injury provokes adverse left ventricular remodeling in dysferlin-deficient hearts through a pathway that involves TIRAP dependent signaling. <i>Scientific Reports</i> , 2020, 10, 14129.	3.3	5
306	Frailty Measures of Patient-reported Activity and Fatigue May Predict 1-year Outcomes in Ambulatory Advanced Heart Failure: A Report From the REVIVAL Registry. <i>Journal of Cardiac Failure</i> , 2022, 28, 765-774.	1.7	5

#	ARTICLE	IF	CITATIONS
307	Modulation of left ventricular dilation remodeling with epicardial restraint devices in postmyocardial infarction heart failure. <i>Current Heart Failure Reports</i> , 2009, 6, 229-235.	3.3	4
308	Statement Regarding the Pre and Post Market Assessment of Durable, Implantable Ventricular Assist Devices in the United States. <i>Annals of Thoracic Surgery</i> , 2012, 94, 2147-2158.	1.3	4
309	Statement Regarding the Pre and Post Market Assessment of Durable, Implantable Ventricular Assist Devices in the United States: Executive Summary. <i>Annals of Thoracic Surgery</i> , 2012, 94, e163-e168.	1.3	4
310	The Treatment of Heart Failure in the 21st Century: Is the Glass Half Empty or Half Full?. <i>Methodist DeBaake Cardiovascular Journal</i> , 2021, 9, 3.	1.0	4
311	Colchicine and the Failing Heart. <i>JACC: Heart Failure</i> , 2014, 2, 138-140.	4.1	4
312	Association of quality of life with anticoagulant control in patients with heart failure: The Warfarin and Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) trial. <i>International Journal of Cardiology</i> , 2014, 177, 715-717.	1.7	4
313	Can Mr. Trump Make Translational Research Great Again?. <i>JACC Basic To Translational Science</i> , 2017, 2, 101-103.	4.1	4
314	Recognition of self-DNA drives cardiac inflammation: why broken hearts fail. <i>Nature Medicine</i> , 2017, 23, 1400-1401.	30.7	4
315	Incident Heart Failure in Chronic Inflammatory Diseases. <i>JACC: Heart Failure</i> , 2020, 8, 499-500.	4.1	4
316	An early relook identifies high-risk trajectories in ambulatory advanced heart failure. <i>Journal of Heart and Lung Transplantation</i> , 2022, 41, 104-112.	0.6	4
317	Restoring public trust in scientific research by reducing conflicts of interest. <i>Journal of Clinical Investigation</i> , 2019, 129, 3971-3973.	8.2	4
318	Doppler and two-dimensional echocardiographic diagnosis of Björk-Shiley prosthetic valve malfunction: Importance of interventricular septal motion and the timing of onset of valve flow. <i>Journal of the American College of Cardiology</i> , 1986, 8, 971-974.	2.8	3
319	Cardiac Remodeling as Therapeutic Target: Treating Heart Failure with Cardiac Support Devices. <i>Heart Failure Reviews</i> , 2005, 10, 93-94.	3.9	3
320	Molecular Imaging and the Failing Heart. <i>JACC: Cardiovascular Imaging</i> , 2009, 2, 199-201.	5.3	3
321	The Heart Failure Society of America in 2020: A Vision for the Future. <i>Journal of Cardiac Failure</i> , 2012, 18, 90-93.	1.7	3
322	Statement Regarding the Pre and Post Market Assessment of Durable, Implantable Ventricular Assist Devices in the United States: Executive Summary. <i>Circulation: Heart Failure</i> , 2013, 6, 145-150.	3.9	3
323	Light Chains and the Failing Heart. <i>JACC: Heart Failure</i> , 2015, 3, 626-628.	4.1	3
324	Heart Failure Severity and Quality of Warfarin Anticoagulation Control (From the WARCEF Trial). <i>American Journal of Cardiology</i> , 2018, 122, 821-827.	1.6	3

#	ARTICLE	IF	CITATIONS
325	Heart Failure 2021. Circulation Research, 2021, 128, 1419-1420.	4.5	3
326	Myocardial dysfunction in septic shock: basic mechanisms and emerging concepts. Current Opinion in Anaesthesiology, 1994, 7, 26-32.	2.0	2
327	Heart failure 2008: an update for clinicians. Current Opinion in Cardiology, 2008, 23, 227.	1.8	2
328	Highlights of the 2009 Scientific Sessions of the Heart Failure Society of America, Boston, MA, September 13-16, 2009. Journal of Cardiac Failure, 2010, 16, 2-8.	1.7	2
329	Guidelines are Merely Guidelines. Journal of Cardiac Failure, 2011, 17, 208-209.	1.7	2
330	Searching for the perfect agent to improve cardiac contractility. Lancet, The, 2016, 388, 2845-2847.	13.7	2
331	Potential Effect of Brexit on Cardiovascular Translational Science. JACC Basic To Translational Science, 2016, 1, 416-417.	4.1	2
332	Will the Precision Medicine Initiative Transform Cardiovascular Translational Research?. JACC Basic To Translational Science, 2016, 1, 298-299.	4.1	2
333	High-Resolution Chromatin Mapping in Heart Failure. Circulation, 2017, 136, 1626-1628.	1.6	2
334	Aspirin Does Not Increase Heart Failure Events in Heart Failure Patients. JACC: Heart Failure, 2017, 5, 603-610.	4.1	2
335	Diagnostic accuracy of damage-associated molecular patterns (DAMPs) in patients with heart failure with a reduced ejection fraction. Journal of Clinical and Translational Science, 2017, 1, 208-209.	0.6	2
336	Current Education of Physicians: Lost in Translation?. JACC Basic To Translational Science, 2019, 4, 655-657.	4.1	2
337	Targeted gene silencing of tumor necrosis factor attenuates the negative inotropic effects of lipopolysaccharide in isolated contracting cardiac myocytes. Texas Heart Institute Journal, 2008, 35, 16-21.	0.3	2
338	Activation of Inflammatory Mediators in Heart Failure. , 2011, , 163-184.		1
339	Update: Shortness of Breath. Circulation, 2014, 129, e447-9.	1.6	1
340	Diabetic Cardiomyopathy: Distinct and Preventable Entity or Inevitable Consequence?. Current Cardiovascular Risk Reports, 2014, 8, 1.	2.0	1
341	JACC: Basic to Translational Science. JACC Basic To Translational Science, 2016, 1, 190-191.	4.1	1
342	The 2017 March for Science. JACC Basic To Translational Science, 2017, 2, 344-345.	4.1	1

#	ARTICLE	IF	CITATIONS
343	Empagliflozin and the Prevention of Heart Failure. JACC Basic To Translational Science, 2017, 2, 355-357.	4.1	1
344	What Are the Off-Target Effects of Planar Lipid Bilayers For Translational Investigators?. JACC Basic To Translational Science, 2019, 4, 132-133.	4.1	1
345	Pulse pressure and prognosis in patients with heart failure with reduced ejection fraction. European Journal of Clinical Investigation, 2019, 49, e13092.	3.4	1
346	Role of Innate Immunity in Heart Failure. , 2020, , 103-114.e2.		1
347	Abstract 1949: The Protein Kinase MAP4K4 Is Activated in Failing Human Hearts and Mediates Cardiomyocyte Apoptosis in Experimental Models, in vitro and in vivo. Circulation, 2007, 116, .	1.6	1
348	Cardiac Adrenergic Activation in Heart Failure With Preserved Ejection Fraction. JACC Basic To Translational Science, 2022, 7, 128-130.	4.1	1
349	Making Science Fun Again. JACC Basic To Translational Science, 2022, 7, 311-312.	4.1	1
350	Endothelin Antagonism and the Failing Heart: an Unfilled Promise, an Unmet Need, or an Unanswered Question?. Journal of Molecular and Cellular Cardiology, 2002, 34, 1131-1133.	1.9	0
351	Can valsartan reduce the occurrence of atrial fibrillation in heart failure patients?. Nature Clinical Practice Cardiovascular Medicine, 2005, 2, 502-503.	3.3	0
352	Angiotensin Receptor Blockers in the Treatment of Heart Failure. , 0, , 44-56.		0
353	Mechanisms of idiopathic dilated cardiomyopathies. Current Opinion in Organ Transplantation, 2006, 11, 553-559.	1.6	0
354	Improved propensity matching for heart failure using neural gas and self-organizing maps. , 2009, , .		0
355	Unsupervised cluster analysis and mortality risk in the Digitalis Investigation Group (DIG) trial of heart failure. , 2009, , .		0
356	Letter by Taylor et al Regarding Article, "Hydralazine and Isosorbide Dinitrate in Heart Failure: Historical Perspectives, Mechanisms, and Future Directions" Circulation, 2011, 124, e778; author reply e779.	1.6	0
357	The Role of Cytokines in Clinical Heart Failure. , 2015, , 191-203.		0
358	Training the Next Generation of Translational Cardiovascular Investigators. JACC Basic To Translational Science, 2016, 1, 554-556.	4.1	0
359	JACC: Basic to Translational Science. Journal of the American College of Cardiology, 2017, 69, 1093-1094.	2.8	0
360	Deus Ex Machina. JACC Basic To Translational Science, 2017, 2, 227-228.	4.1	0

#	ARTICLE	IF	CITATIONS
361	Inflammatory Mediators in Heart Failure. , 2018, , 33-50.		0
362	Can One Person Make a Difference?. JACC Basic To Translational Science, 2019, 4, 868-869.	4.1	0
363	Alterations in Ventricular Structure. , 2020, , 166-180.e3.		0
364	Why Do Medical Journals Exist in the 21st Century?. JACC Basic To Translational Science, 2020, 5, 969-970.	4.1	0
365	JACC: Basic to Translational Science and Preprint Servers. JACC Basic To Translational Science, 2020, 5, 107-108.	4.1	0
366	Associations of methyl donor and methylation inhibitor levels during anti-oxidant therapy in heart failure. Journal of Physiology and Biochemistry, 2021, 77, 295-304.	3.0	0
367	The clinical experience with anti-cytokine therapy in heart failure. , 2003, , 95-110.		0
368	Abstract 205: Dysfunction of the 19S Proteasome Contributes to Adverse Cardiac Remodeling in Mice With Cardiac Restricted Overexpression of Tumor Necrosis Factor. Circulation, 2007, 116, .	1.6	0
369	Abstract 2915: Circulating Fas in Subjects with Acute Cardiomyopathy and Myocarditis: Results from IMAC 1. Circulation, 2007, 116, .	1.6	0
370	Abstract 1770: Proteasome Switching is Associated with Adverse Cardiac Remodeling in a Transgenic Mouse Model of Sustained Inflammatory Signaling. Circulation, 2008, 118, .	1.6	0
371	The role of cytokines in inflammation-induced cardiomyopathy: Pathogenesis and therapeutic implications. , 2010, , 171-181.		0
372	Molecular and Cellular Mechanisms for Myocardial Recovery. , 2011, , 119-133.		0
373	Device Autonomic Regulation Therapy in Patients with Heart Failure and Reduced Ejection Fraction. Journal of Atrial Fibrillation, 2020, 13, 2409.	0.5	0
374	Recent Insights into the Molecular Pathophysiology of Viral Myocarditis. , 2005, , 145-153.		0
375	The Role of Cardiac Restraint Devices in the Treatment of Patients with Dilated Cardiomyopathy. , 0, , 59-67.		0
376	Could Neprilysin Be Already Inhibited by BNP in the LIFE Trial? Reply. JAMA Cardiology, 2022, , .	6.1	0